Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®

STOCKHOLM, Sept. 1, 2026 /PRNewswire/ -- BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that Canada's Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible patients in Canada with mild cognitive...